Emergence of Oseltamivir-Resistant H7N9 Influenza Viruses in Immunosuppressed Cynomolgus Macaques

• Published in: The Journal of infectious diseases Vol. 216; no. 5; pp. 582 - 593
• Main Authors: Kiso, Maki, Iwatsuki-Horimoto, Kiyoko, Yamayoshi, Seiya, Uraki, Ryuta, Ito, Mutsumi, Nakajima, Noriko, Yamada, Shinya, Imai, Masaki, Kawakami, Eiryo, Tomita, Yuriko, Fukuyama, Satoshi, Itoh, Yasushi, Ogasawara, Kazumasa, Lopes, Tiago J. S., Watanabe, Tokiko, Moncla, Louise H., Hasegawa, Hideki, Friedrich, Thomas C., Neumann, Gabriele, Kawaoka, Yoshihiro
• Format: Journal Article
• Language: English
• Published: US Oxford University Press 01.09.2017
• Subjects: Animals; Antiviral Agents - therapeutic use; Dose-Response Relationship, Drug; Drug Resistance, Multiple, Viral; Female; Hemagglutinin Glycoproteins, Influenza Virus - genetics; Hemagglutinin Glycoproteins, Influenza Virus - metabolism; High-Throughput Nucleotide Sequencing; Immunocompromised Host; Influenza A Virus, H7N9 Subtype - drug effects; Influenza A Virus, H7N9 Subtype - physiology; Macaca fascicularis - virology; Male; Neuraminidase - antagonists & inhibitors; Neuraminidase - metabolism; Orthomyxoviridae Infections - drug therapy; Orthomyxoviridae Infections - veterinary; Orthomyxoviridae Infections - virology; Oseltamivir - therapeutic use; Virus Replication; VIRUSES; immunosuppression; nonhuman primates; Influenza virus; oseltamivir resistance

Antiviral compounds (eg, the neuraminidase inhibitor oseltamivir) are invaluable for the treatment of individuals infected with influenza A viruses of the H7N9 subtype (A[H7N9]), which have infected and killed hundreds of persons. However, oseltamivir treatment often leads to the emergence of resist...